Scholar Rock Holding's Days Sales Outstanding for the
three
months ended in Dec. 2023 was 0.
Scholar Rock Holding's Days Inventory for the
three
months ended in Dec. 2023 was .
Scholar Rock Holding's Days Payable for the
three
months ended in Dec. 2023 was .
Therefore, Scholar Rock Holding's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2023 was 0.00.
Scholar Rock Holding Cash Conversion Cycle Historical Data
The historical data trend for Scholar Rock Holding's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Scholar Rock Holding's Cash Conversion Cycle
For the Biotechnology subindustry, Scholar Rock Holding's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding's Cash Conversion Cycle Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's Cash Conversion Cycle falls into.
Scholar Rock Holding Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Scholar Rock Holding's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (NAS:SRRK) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Scholar Rock Holding Cash Conversion Cycle Related Terms
Thank you for viewing the detailed overview of Scholar Rock Holding's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Scholar Rock Holding (Scholar Rock Holding) Business Description
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRRK has been successfully added to your 